Claims:

1. A method of preparing an antibody pharmaceutical formulation having a viscosity of 10 cP or less comprising, during an ultrafiltration/diafiltration step buffer, exchanging a composition comprising the antibody with a diafiltration buffer comprising (a) at least 20 mM calcium acetate and (b) a polyol, and wherein the buffer exchange occurs at a temperature between 30°C and 40°C.

2. The method of claim 1, wherein the composition comprises the antibody at a concentration of at least 90 mg/mL.

3. The method of claim 1, wherein the composition comprises the antibody at a concentration of at least 120 mg/mL.

4. The method of any one of claims 1-3, wherein the exchanging step occurs at 37°C.

5. The method of claims 1-4, wherein the diafiltration buffer comprises 23 mM calcium acetate.

6. The method of any one of claims 1-5, wherein the polyol is sucrose.

7. The method of claim 6, wherein diafiltration buffer comprises sucrose present at a concentration of 1% to 15%.

8. The method of claim 6, wherein the diafiltration buffer comprises sucrose at a concentration of about 7%.

9. The method of any one of claims 1-8, further comprising the step of filtering the pharmaceutical formulation.

10. The method of any one of claims 1-9, further comprising the step of aliquoting the pharmaceutical formulation into a drug product form.

11. The method of any one of claims 1-10, wherein the antibody is romosozumab, abciximab, adalimumab, alemtuzumab, basiliximab, belimumab, bevacizumab, brentuximab vedotin, canakinumab, cetuximab, certolizumab pegol, daclizumab, denosumab, eculizumab, efalizumab, gemtuzumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, nivolumab, ofatumumab, omalizumab, palivizumab,

panitumumab, ranibizumab, rituximab, tocilizumab, tositumomab, trastuzumab or ustekinumab, vedolizumab.

12. The method of any one of claims 1-11, wherein the pharmaceutical formulation after the exchanging step comprises at least 50 mM acetate and 12 mM calcium.